sorafenib has been researched along with endothelin-1 in 2 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (endothelin-1) | Trials (endothelin-1) | Recent Studies (post-2010) (endothelin-1) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 12,740 | 632 | 3,394 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Alpini, G; Fallon, MB; Hu, B; Venter, J; Wu, W; Yang, W; Zhang, J | 1 |
Cho, EJ; Cho, KH; Hwang, CY; Kim, YJ; Lee, JH; Lee, KB; Lee, S; Noh, H; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ | 1 |
2 other study(ies) available for sorafenib and endothelin-1
Article | Year |
---|---|
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.
Topics: Animals; Common Bile Duct; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hepatopulmonary Syndrome; Ligation; Lung; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Endothelin-1; Humans; Liver Neoplasms; Mice; Sorafenib; Systems Analysis; Xenograft Model Antitumor Assays | 2022 |